Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14251810 | 1.00 | MEN1 (0.43) | MEN1KMT2ANR1H2NR1H3ALDH1A1 | |
| SCHEMBL4043624 | 0.92 | MEN1 (0.40) | MEN1KMT2ANR1H2NR1H3ALDH1A1 | |
| SCHEMBL4041583 | 0.89 | HPGD (0.44) | MEN1KMT2AALDH1A1TSHRFKBP1A | |
| SCHEMBL27619275 | 0.86 | ALDH1A1 (0.41) | MEN1KMT2ANR1H2ALDH1A1TSHR | |
| SCHEMBL4841744 | 0.85 | PDK1 (0.52) | MEN1KMT2ATSHRCACNA1ACACNA2D1 | |
| SCHEMBL6335353 | 0.85 | PARP1 (0.54) | MEN1KMT2AFKBP1AMMP1MMP3 | |
| SCHEMBL4040548 | 0.84 | SETD7 (0.46) | MEN1KMT2AALDH1A1CACNA1ACACNA2D1 | |
| SCHEMBL11304352 | 0.84 | KMT2A (0.43) | MEN1KMT2ANR1H2NR1H3ALDH1A1 | |
| SCHEMBL1849268 | 0.84 | NR1H2 (0.54) | NR1H2NR1H3ALDH1A1HSD17B10MMP1 | |
| SCHEMBL919744 | 0.84 | NR1H2 (0.54) | NR1H2NR1H3ALDH1A1HSD17B10MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210749-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-07-27 | — | — | US | disclosed |
| US-9662327-B2 | Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer | AGIOS PHARMACEUTICALS, INC (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2721033-B1 | COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USES AS IDH1 MUTANTS INHIBITORS FOR TREATING CANCERS | AGIOS PHARMACEUTICALS INC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2721033-B1 | COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USES AS IDH1 MUTANTS INHIBITORS FOR TREATING CANCERS | AGIOS PHARMACEUTICALS INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20140206673-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2721033-A1 | COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USES AS IDH1 MUTANTS INHIBITORS FOR TREATING CANCERS | Agios Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012171506-A1 | COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USES AS IDH1 MUTANTS INHIBITORS FOR TREATING CANCERS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012171506-A1 | COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USES AS IDH1 MUTANTS INHIBITORS FOR TREATING CANCERS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-5849746-A | Substituted 1,4-piperazine-heteroaryl derivatives as 5-HT1D receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 1998-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | MEN1 4127/4885KMT2A 4370/4885NR1H2 2169/4885 |
| US-20170210749-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | RNASE1, GZMB, ANXA2 | MEN1 1225/4885KMT2A 2810/4885NR1H2 477/4885 |
| US-20140206673-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | RNASE1, GZMB, ANXA2 | MEN1 1225/4885KMT2A 2810/4885NR1H2 477/4885 |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | MEN1 4666/4885KMT2A 922/4885NR1H2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.